BNP PARIBAS EMISSIONS UND HANDELSGESELLSCHAFT | Real-time Boerse Frankfurt Warrants 05:15:17 2022-02-04 EST | ||
| 1,000 EUR | -.--% |
|
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
Static data
| Product type | sonstige Zertifikate |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| WKN | PF99KS |
| ISIN | DE000PF99KS5 |
| Date issued | 2022-03-04 |
| Strike | 250 $ |
| Maturity | 2027-03-01 (977 Days) |
| Parity | 0.25 : 1 |
| Emission price | 1,000 € |
| Emission volume | N/A |
| Settlement | Beides |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1,000 € |
|---|---|
| Lowest since issue | 1,000 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
909
USD
Average target price
860.5
USD
Spread / Average Target
-5.33%
- Stock Market
- Certificates
- Certificat
